Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CD84 CAR-T Therapy for Relapsed/Refractory AML
NCT06786299Phase 1Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Feb 2025
- Primary completion
- Oct 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD84 CAR T-cells in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Maximal Tolerable Dose at 28 days, Recommended Phase II Dose at 28 days and 1 more. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
CD84 CAR T-cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06786299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06786299.